Kaplan-Meier curves of progression-free survival (PFS) and overall... | Download Scientific Diagram
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates | Journal for ImmunoTherapy of Cancer
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram
Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram
JCM | Free Full-Text | A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation | HTML
Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram
Overall survival and progression-free survival. The median follow-up... | Download Scientific Diagram
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Progression-Free Survival for WM | IMBRUVICA® (ibrutinib)
Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram
Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram
Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
